ライフサイエンスコーパス: antibody-mediated rejection

1 R ELISA and microvascular injury observed in antibody mediated rejection.

2 All evaluable explanted grafts experienced antibody-mediated rejection.

3 1), there was a nonsignificant difference in antibody-mediated rejection.

4 ensitization and prevention and treatment of antibody-mediated rejection.

5 ntibody manifests characteristic features of antibody-mediated rejection.

6 ntial therapeutic target in the treatment of antibody-mediated rejection.

7 ) is part of the Banff definition of chronic antibody-mediated rejection.

8 undergoing desensitization or treatment for antibody-mediated rejection.

9 athology, in particular for the diagnosis of antibody-mediated rejection.

10 Six-month protocol biopsies showed no antibody-mediated rejection.

11 truggle with the diagnosis and management of antibody-mediated rejection.

12 plantation of non-renal organs, and to treat antibody-mediated rejection.

13 no satisfactory therapies for prevention of antibody-mediated rejection.

14 be used to test biopsies for the presence of antibody-mediated rejection.

15 pressed, indicating separation of T-cell and antibody-mediated rejection.

16 ation of macrophages in the allograft during antibody-mediated rejection.

17 ion of the complement cascade is involved in antibody-mediated rejection.

18 pful in excluding chronic, Banff category II antibody-mediated rejection.

19 ing the need for a nonhuman primate model of antibody-mediated rejection.

20 mixed chronic T-cell and concurrent chronic antibody-mediated rejection.

21 ic antibodies and 7% of patients experienced antibody-mediated rejection.

22 t of donor-specific anti-HLA antibodies, and antibody-mediated rejection.

23 denced by a fourfold increase in the risk of antibody-mediated rejection.

24 in 25 patients with biopsy-confirmed chronic antibody-mediated rejection.

25 lved in ABOi transplantation and subclinical antibody-mediated rejection.

26 h is likely related to a higher incidence of antibody-mediated rejection.

27 ual rebound of donor-specific antibodies and antibody-mediated rejection.

28 ing list patients and a better prediction of antibody-mediated rejection.

29 tential of TNT009 for preventing or treating antibody-mediated rejection.

30 Complement may play a key role in antibody-mediated rejection.

31 100 recipients, P < 0.01), with an excess of antibody-mediated rejections.

32 s/100 recipients, p<0.01), with an excess of antibody-mediated rejections.

33 The incidence of antibody-mediated rejection (25% vs. 12.5%, P=0.008) and

34 nd five DSA- (2%) patients developed chronic antibody-mediated rejection (3%).

35 ls (80% vs 55%), especially a higher rate of antibody-mediated rejections (55% vs 11%, P < 0.01) with

36 R (24.3 [11.2, 44.8], P < 0.001, n = 9); and antibody-mediated rejection (6.0 [3.3, 13.7], P = 0.002,

37 reased risk for T cell-mediated rejection or antibody-mediated rejection (68% vs 41%, P = 0.01) and f

38 re also associated with an increased rate of antibody-mediated rejection, a more severe graft injury

39 t decade, the diagnostic precision for acute antibody-mediated rejection (aABMR) in kidney transplant

40 Overall, 51 (40.8%) patients had acute antibody-mediated rejection (aABMR), 36 (28.8%) patients

41 on report of the incidence of combined acute antibody-mediated rejection (ABMR) + acute cellular reje

42 st Banff 2013 report recognizes acute/active antibody-mediated rejection (ABMR) and C4d staining with

43 cific antibodies (dnDSA) are associated with antibody-mediated rejection (ABMR) and graft failure aft

44 expression glomerular of capillaries during antibody-mediated rejection (ABMR) are poorly understood

45 Antibody-mediated rejection (ABMR) can occur in patients

46 of this study was to determine how the Banff antibody-mediated rejection (ABMR) classification for ki

47 A) are considered as reliable biomarkers for antibody-mediated rejection (ABMR) diagnosis.

48 e clinical impact of updates of C4d-negative antibody-mediated rejection (ABMR) from the 2013 meeting

49 Although antibody-mediated rejection (ABMR) has been long recogni

50 nt glomerulitis (G) is associated with acute antibody-mediated rejection (ABMR) in the presence of do

51 Antibody-mediated rejection (ABMR) is a leading cause of

52 Late antibody-mediated rejection (ABMR) is a leading cause of

53 Late antibody-mediated rejection (ABMR) is a leading cause of

54 viding renewed support for the paradigm that antibody-mediated rejection (ABMR) is an important clini

55 Antibody-mediated rejection (ABMR) is the leading cause

56 olecules as diagnostic/prognostic markers of antibody-mediated rejection (ABMR) is unknown.

57 ant rates in highly sensitized patients, but antibody-mediated rejection (ABMR) remains a concern.

58 able for the early assessment of response to antibody-mediated rejection (ABMR) therapies in kidney a

59 No confirmed cases of clinical antibody-mediated rejection (ABMR) were present in the p

60 atients undergoing acute cellular rejection, antibody-mediated rejection (ABMR), and delayed graft fu

61 nd points included rates of transplantation, antibody-mediated rejection (ABMR), and renal function.

62 lement may contribute to the pathogenesis of antibody-mediated rejection (ABMR).

63 ansplant tolerance, and protecting from late antibody-mediated rejection (ABMR).

64 MR), and 142 (14%) patients with subclinical antibody-mediated rejection (ABMR).

65 osis of T cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR).

66 rejection (TCMR), either pure or mixed with antibody-mediated rejection (ABMR).

67 l-mediated rejection (TCMR), borderline, and antibody-mediated rejection (ABMR).

68 ng was associated with an increased risk for antibody-mediated rejection (ABMR).

69 both in all kidneys and in kidneys with pure antibody-mediated rejection (ABMR).

70 se biopsy specimens demonstrate histology of antibody-mediated rejection (ABMR).

71 any rejection (T cell-mediated rejection or antibody-mediated rejection [ABMR]) and controls (no rej

72 Defining mechanisms of antibody-mediated rejection, accommodation, and toleranc

73 fter lung transplantation is associated with antibody mediated rejection, acute cellular rejection, a

74 in HLA-sensitized patients and how to treat antibody-mediated rejection after ABO-compatible HLA-inc

75 d to describe endothelial cell resistance to antibody-mediated rejection after ABO-incompatible kidne

76 y contribute to acute cellular rejection and antibody-mediated rejection after liver transplantation.

77 anti-HLA antibodies (DSA) (67% and 82%) and antibody mediated rejection (AMR) (66% and 89%) when com

78 ence of T cell-mediated rejection (9.2%) and antibody-mediated rejection (AMR) (13.8%).

79 s. 34.8%, P=0.01), including higher rates of antibody-mediated rejection (AMR) (32.3% vs. 7.1%, P<0.0

80 34 kidney recipients, 19 with biopsy-proven antibody-mediated rejection (AMR) + and 15 who were AMR-

81 Antibody-mediated rejection (AMR) accounts for >50% of k

82 Treatment of patients with antibody-mediated rejection (AMR) after kidney transplan

83 nimals (n = 6) experienced graft loss due to antibody-mediated rejection (AMR) after kidney transplan

84 ecific antibodies (DSAs) are associated with antibody-mediated rejection (AMR) and allograft loss.

85 pecific antibodies (DSA) are associated with antibody-mediated rejection (AMR) and allograft loss.

86 lpha1-Tubulin (KAT) in pathogenesis of acute antibody-mediated rejection (AMR) and cardiac allograft

87 ibodies (AT1R-abs) have been associated with antibody-mediated rejection (AMR) and decreased graft su

88 ities associated with bortezomib therapy for antibody-mediated rejection (AMR) and desensitization wa

89 ecific antibodies (DSA) play a major role in antibody-mediated rejection (AMR) and graft dysfunction.

90 nor-specific antibodies play a major role in antibody-mediated rejection (AMR) and graft dysfunction.

91 e between indolent and harmful dnDSA causing antibody-mediated rejection (AMR) and graft loss.

92 K) cells localize in the microcirculation in antibody-mediated rejection (AMR) and have been postulat

93 donor-specific anti-HLA antibodies (DSA) on antibody-mediated rejection (AMR) and kidney allograft f

94 o DSA/complement predominates in early-acute antibody-mediated rejection (AMR) and presents with EC s

95 A alloantibodies may cause acute and chronic antibody-mediated rejection (AMR) and significantly comp

96 tion is associated with an increased rate of antibody-mediated rejection (AMR) and subsequent transpl

97 0%) patients with AAD and 1 (3%) control had antibody-mediated rejection (AMR) by endomyocardial biop

98 hallenges facing clinical transplantation is antibody-mediated rejection (AMR) caused by anti-donor H

99 Antibody-mediated rejection (AMR) contributes to heart a

100 Histology remains a cornerstone for antibody-mediated rejection (AMR) diagnosis.

101 Antibody-mediated rejection (AMR) driven by the developm

102 n (group 1, n=20) or a recent previous acute antibody-mediated rejection (AMR) episode (group 2, n=8)

103 Antibody-mediated rejection (AMR) has been identified am

104 Antibody-mediated rejection (AMR) has emerged as an impo

105 ficacy of plasma cell targeted therapies for antibody-mediated rejection (AMR) has not been defined i

106 ive Syk inhibitor (GS-492429) could suppress antibody-mediated rejection (AMR) in a rat model of AMR

107 Antibody-mediated rejection (AMR) in cardiac allograft r

108 C4d-assisted recognition of antibody-mediated rejection (AMR) in formalin-fixed para

109 (MICA) are associated with the diagnosis of antibody-mediated rejection (AMR) in heart transplant re

110 though several strategies for treating early antibody-mediated rejection (AMR) in kidney transplants

111 Barcelona focused on the multiple aspects of antibody-mediated rejection (AMR) in lung transplantatio

112 d efficacy of eculizumab in preventing acute antibody-mediated rejection (AMR) in sensitized recipien

113 tiveness of eculizumab for the prevention of antibody-mediated rejection (AMR) in the setting of rena

114 lthough the clinical significance of DSA and antibody-mediated rejection (AMR) in upper extremity tra

115 Antibody-mediated rejection (AMR) is a leading cause of

116 Antibody-mediated rejection (AMR) is a major cause of ki

117 Antibody-mediated rejection (AMR) is a major cause of ki

118 Antibody-mediated rejection (AMR) is a major risk for re

119 Active antibody-mediated rejection (AMR) is a potentially devas

120 Antibody-mediated rejection (AMR) is a principal cause o

121 Antibody-mediated rejection (AMR) is a recognized cause

122 Antibody-mediated rejection (AMR) is a severe form of re

123 dentifying immune mechanisms responsible for antibody-mediated rejection (AMR) is an important goal.

124 Antibody-mediated rejection (AMR) is an important proble

125 Antibody-mediated rejection (AMR) is an increasingly rec

126 Antibody-mediated rejection (AMR) is an uncommon, but ch

127 Treatment of acute antibody-mediated rejection (AMR) is based on a combinat

128 In heart transplantation, antibody-mediated rejection (AMR) is diagnosed and grade

129 Acute antibody-mediated rejection (AMR) is responsible for up

130 allograft failure after an episode of acute antibody-mediated rejection (AMR) may help the outcome o

131 Antibody-mediated rejection (AMR) of most solid organs i

132 n both ischemia-reperfusion injury (IRI) and antibody-mediated rejection (AMR) of solid organ allogra

133 ral killer (NK) cell-associated genes during antibody-mediated rejection (AMR) of the renal allograft

134 nsplantation) anti-HLA-DSA were diagnosed as antibody-mediated rejection (AMR) or AMR+T-cell-mediated

135 Antibody-mediated rejection (AMR) plays an important rol

136 pment of donor-specific antibodies (DSA) and antibody-mediated rejection (AMR) posttransplant.

137 Antibody-mediated rejection (AMR) represents one of the

138 Antibody-mediated rejection (AMR) resulting in transplan

139 A proposed chronic antibody-mediated rejection (AMR) score has recently pre

140 Active antibody-mediated rejection (AMR) that occurs during the

141 Rituximab is used for desensitization and antibody-mediated rejection (AMR) treatment by targeting

142 (DSA) and its association with occurrence of antibody-mediated rejection (AMR) using a recently devel

143 The risk of antibody-mediated rejection (AMR) was higher in the dnDS

144 Among transplant recipients, antibody-mediated rejection (AMR) was more frequent in g

145 transplant recipients with an early or late antibody-mediated rejection (AMR), acute cellular reject

146 nt, de novo donor-specific antibodies (DSA), antibody-mediated rejection (AMR), acute cellular reject

147 antidonor antibodies results in accelerated antibody-mediated rejection (AMR), complement activation

148 rapy) and systematic treatment of subsequent antibody-mediated rejection (AMR), even when subclinical

149 In the treatment of refractory antibody-mediated rejection (AMR), splenectomy has been

150 apy.Fifteen (29%) of 52 patients experienced antibody-mediated rejection (AMR), whereas 37 (71%) pati

151 with improved renal allograft survival after antibody-mediated rejection (AMR).

152 rkers are needed that identify patients with antibody-mediated rejection (AMR).

153 capillaries is a well-established feature of antibody-mediated rejection (AMR).

154 f transplantation leads to acute and chronic antibody-mediated rejection (AMR).

155 d arrays may not inevitably indicate ongoing antibody-mediated rejection (AMR).

156 aft function as well as in acute and chronic antibody-mediated rejection (AMR).

157 icrovascular inflammation leading to chronic antibody-mediated rejection (AMR).

158 (CNI) toxicity while effectively preventing antibody-mediated rejection (AMR).

159 DCC) is an important pathway responsible for antibody-mediated rejection (AMR).

160 r before transplantation or as treatment for antibody-mediated rejection (AMR).

161 pathology, particularly in acute and chronic antibody-mediated rejection (AMR).

162 is associated with increased mortality from antibody-mediated rejection (AMR).

163 ailure of desensitization and development of antibody-mediated rejection (AMR).

164 d transplant that has acquired resistance to antibody-mediated rejection (AMR).

165 ting of T cell-mediated rejection (TCMR) and antibody-mediated rejection (AMR).

166 SA+ patients who met Banff 2013 criteria for antibody-mediated rejection (AMR).

167 plant recipients increases the risk of acute antibody-mediated rejection (AMR).

168 positive group (P < 0.001), primarily due to antibody-mediated rejection (AMR, 13% vs. 1.8%, P < 0.00

169 Three antibody-mediated rejections (AMRs) occurred without det

170 ased donors, new immunosuppression regimens, antibody mediated rejection and the regulatory environme

171 kidney transplant recipient with refractory antibody-mediated rejection and a highly sensitized hear

172 nguished acute cellular rejection from acute antibody-mediated rejection and borderline rejection (AU

173 rphologic evidence of an association between antibody-mediated rejection and de novo MG, because both

174 bodies are associated with increased risk of antibody-mediated rejection and decreased allograft surv

175 esearch is needed regarding its use for both antibody-mediated rejection and desensitization.

176 te and chronic T cell-mediated rejection and antibody-mediated rejection and discuss the additive val

177 and potentially progressive diseases such as antibody-mediated rejection and glomerulonephritis.

178 is a major risk factor for acute and chronic antibody-mediated rejection and graft loss after all sol

179 pecific antibodies (DSA) are associated with antibody-mediated rejection and graft loss.

180 fic antibodies (dnDSA) and can contribute to antibody-mediated rejection and graft loss.

181 avoided due to their strong association with antibody-mediated rejection and graft loss.

182 s from transplantation patients with chronic antibody-mediated rejection and in panel-reactive antibo

183 ransplant recipients and are associated with antibody-mediated rejection and long-term graft loss.

184 odel with which to investigate mechanisms of antibody-mediated rejection and novel therapeutic approa

185 dies (donor-specific antibody) contribute to antibody-mediated rejection and poor long-term graft sur

186 ind any association between the frequency of antibody-mediated rejection and pretransplant proportion

187 riteria for the diagnosis of liver allograft antibody-mediated rejection and provide a comprehensive

188 tibodies that led to clinical improvement of antibody-mediated rejection and to heart graft access.

189 acute T cell-mediated rejection and 26 acute antibody-mediated rejection) and 32 urine samples from 3

190 L-6 in mediation of cell-mediated rejection, antibody-mediated rejection, and chronic allograft vascu

191 st-transplant donor-specific HLA antibodies, antibody-mediated rejection, and early transplant glomer

192 ary macrophage infiltration is a hallmark of antibody-mediated rejection, and macrophages are importa

193 may be associated with cell-mediated and/or antibody-mediated rejection, and portend an adverse outc

194 on of de novo donor-specific antibody (DSA), antibody-mediated-rejection, and unfavorable transplanta

195 T assay to detect AR (T cell-mediated and/or antibody-mediated rejection) as compared to a concomitan

196 nff 3-Borderline, Banff 4-I/II/III), Banff-2 antibody-mediated rejection, Banff-5 interstitial fibros

197 is a diagnostic criterion for chronic active antibody-mediated rejection (CAABMR), with C4d, donor-sp

198 s (dnDSA) is associated with late or chronic antibody-mediated rejection (CAMR) and poor graft outcom

199 The incidence of chronic antibody-mediated rejection (CAMR) based on surveillance

200 T-cell-mediated rejection (TCMR) and chronic antibody-mediated rejection (CAMR) in NHPs.

201 Chronic antibody-mediated rejection (cAMR) results in the majori

202 he allograft might be compromised by chronic antibody-mediated rejection (CAMR), leading to irreversi

203 divided into 3 groups: TOL, n = 10; chronic antibody-mediated rejection (CAMR), n = 12; and T cell-m

204 evels were higher in patients diagnosed with antibody mediated rejection compared to those with no re

205 Antibody-mediated rejection continues to hinder long-ter

206 ed rejection and changes suggestive of acute antibody-mediated rejection, diagnosed after the first y

207 Sensitivity and specificity for antibody-mediated rejection diagnosis was 88% and 68%, r

208 ced acute cellular rejection, and especially antibody-mediated rejection, displayed persistent elevat

209 significantly higher incidence of subsequent antibody-mediated rejection episodes (P < 0.001), but re

210 west DSA thresholds associated with inferior antibody-mediated rejection-free graft survival (75% vs.

211 The transcripts distinguishing antibody-mediated rejection from other conditions were m

212 The role of the complement system in antibody-mediated rejection has been investigated in rel

213 elicit well characterized manifestations of antibody-mediated rejection has not been tested.

214 However, improvement in the diagnosis of antibody-mediated rejection has not yet translated into

215 trophy of skin and other tissues, as well as antibody mediated rejection, have not been reported in a

216 against an RMM were independently at risk of antibody-mediated rejection (HR 8.70 [3.42-22.10], P < .

217 orcine carbohydrate genes necessary to avoid antibody-mediated rejection in a pig-to-human model also

218 ere infection or the treatment/prevention of antibody-mediated rejection in allotransplantation.

219 tible (ABOi) transplantation and subclinical antibody-mediated rejection in HLA-incompatible (HLAi) t

220 nd metallothioneins discriminate subclinical antibody-mediated rejection in HLAi transplantation from

221 ce of serum alloantibody, C4d deposition and antibody-mediated rejection in human patients.

222 ely reflects the glomerular changes of acute antibody-mediated rejection in humans and of a special s

223 lled all diagnostic criteria for acute renal antibody-mediated rejection in humans.

224 the recently described C4d-negative chronic antibody-mediated rejection in humans.

225 and challenges surrounding the diagnosis of antibody-mediated rejection in lung transplantation.

226 be a novel molecular target for controlling antibody-mediated rejection in organ transplantation.

227 dies we have shown an increased incidence of antibody-mediated rejection in patients with pretranspla

228 ve been involved in the majority of cases of antibody-mediated rejection in solid organ transplant re

229 ecipients of kidney transplants experiencing antibody-mediated rejection in the absence of donor-spec

230 We also evaluated for increased evidence of antibody-mediated rejection in the de novo group, as som

231 To confirm the role of antibody-mediated rejection in the sensitized recipients

232 eatment with donor-derived dexDCs induces an antibody-mediated rejection in this islet transplantatio

233 We confirmed our results in a mouse model of antibody-mediated rejection, in which B6.RAG1(-/-) recip

234 These transplants exhibited features of antibody-mediated rejection including capillaritis with

235 Odds for T cell- or antibody-mediated rejection increased by 5% and 12%, res

236 The hazard ratio for antibody-mediated rejection increased linearly with high

237 Antibody-mediated rejection is a leading cause for renal

238 Antibody-mediated rejection is a major complication in r

239 Despite advances in immunosuppression, antibody-mediated rejection is a serious threat to allog

240 Chronic antibody-mediated rejection is an important cause of lat

241 Antibody-mediated rejection is caused in part by increas

242 As a result, antibody-mediated rejection is now widely recognized as

243 Antibody-mediated rejection is the major cause of kidney

244 Antibody-mediated rejection is therefore dependent on Tf

245 ransplantation, especially in the context of antibody-mediated rejection, its histological interpreta

246 ent, with recurrence, subsequently developed antibody-mediated rejection leading to graft failure.

247 hyperacute rejection and 1 episode of early antibody-mediated rejection (<90 days) in the imported V

248 C4d-negative antibody-mediated rejection manifesting as capillaritis

249 ade in solid organ transplantation regarding antibody-mediated rejection may not systematically apply

250 Antibody-mediated rejection occurred in 10 patients (7 p

251 ase-like molecule, as a biomarker of chronic antibody-mediated rejection of human kidneys when measur

252 o models for autoimmune hemolytic anemia and antibody-mediated rejection of organ transplants.

253 recipient T cell sensitization may result in antibody-mediated rejection of renal allografts and intr

254 Twenty-four subjects (61%) developed acute antibody-mediated rejection of the allograft and one pat

255 However, antibody-mediated rejection of the kidney in CLK has bee

256 lthough anti-HLA antibodies (Abs) cause most antibody-mediated rejections of renal allografts, non-an

257 tential, fms-I-treated rats developed severe antibody-mediated rejection on day 8 after transplantati

258 es with scores>0.5, 39 had been diagnosed as antibody-mediated rejection on the basis of histology an

259 sies performed because of graft dysfunction, antibody-mediated rejection or acute tubular necrosis, a

260 t translate into increased acute cellular or antibody-mediated rejection or reduced survival.

261 Arteritis was associated with subsequent antibody-mediated rejection (OR=4.9, 95% CI=1.1-20.8, P=

262 r-specific antibody development (P < .0001), antibody-mediated rejection (P < .0001), as well as all-

263 R or DQ alone, P=0.001, and were at risk for antibody-mediated rejection, P=0.001.

264 Research challenged the conventional view of antibody-mediated rejection pathophysiology and discusse

265 ielded important advancements in the care of antibody-mediated rejection patients and novel drug deve

266 ossmatch result, nearly doubles the risk for antibody-mediated rejection (relative risk [RR], 1.98; 9

267 Diagnosis of antibody-mediated rejection required presence of diffuse

268 inical cellular rejection and 3% subclinical antibody-mediated rejection (SC-ABMR) for the base-case

269 opsy at 1 month showed significantly reduced antibody-mediated rejection scores (P=0.02).

270 ay data to develop classifiers that assigned antibody-mediated rejection scores to each biopsy.

271 ecently been introduced for the treatment of antibody-mediated rejection, target the ubiquitously-exp

272 We have shown in patients with chronic antibody-mediated rejection that B cells control the ind

273 The pathologic manifestations of acute antibody-mediated rejection that has progressed to funct

274 Although widely used as a marker for antibody-mediated rejection, the significance of C4d in

275 the ptc score is a diagnostic criterion for antibody-mediated rejection, the utility of diffuse ptc

276 ll-mediated rejection was more frequent than antibody-mediated rejection throughout follow-up.

277 y assigned diagnoses, including C4d-negative antibody-mediated rejection, to 403 indication biopsies

278 eloped DQ DSAbs were at significant risk for antibody-mediated rejection, transplant glomerulopathy,

279 tients receiving solid organ transplants and antibody-mediated rejection treatment.

280 Antibody-mediated rejection triggered by alloantibody bi

281 transplantation carries an increased risk of antibody-mediated rejection, ultimately these transplant

282 Cellular and antibody-mediated rejection was absent or minimal in ear

283 Antibody-mediated rejection was assessed by morphology/i

284 Antibody-mediated rejection was diagnosed in 6 patients

285 Antibody-mediated rejection was diagnosed using Antibody

286 After belatacept conversion, one antibody-mediated rejection was diagnosed.

287 Antibody-mediated rejection was evident in 15/17 A-Tg gr

288 No evidence for antibody-mediated rejection was found.

289 Antibody-mediated rejection was not observed in A-Tg gra

290 Antibody-mediated rejection was observed in 3 (0.03%) pa

291 C4d staining without antibody-mediated rejection was present in 13 (52%) 25 e

292 iated with unanimity among pathologists that antibody-mediated rejection was present.

293 C4d staining was performed when antibody-mediated rejection was suspected.

294 ts of T cell depletion in the development of antibody-mediated rejection were examined using human CD

295 of immune tolerance, with a low incidence of antibody-mediated rejection, which is in sharp contrast

296 Renal biopsy revealed acute and chronic antibody-mediated rejection with glomerular thrombi and

297 allografts resembled human acute and chronic antibody-mediated rejection with glomerulitis, microthro

298 Most animals experienced antibody-mediated rejection with humoral-response reboun

299 arteritis (v) lesion (TCMRV; n = 78), total antibody-mediated rejection with v lesion (AMRV), which

300 distinguishes T cell-mediated rejection from antibody-mediated rejection, with a cross-validated esti